Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Life Sciences
Synthesis Of Kurasoin B Analogs, J. R. Nielson, Michael A. Christiansen, M. B. Andrus
Synthesis Of Kurasoin B Analogs, J. R. Nielson, Michael A. Christiansen, M. B. Andrus
Chemistry and Biochemistry Faculty Presentations
Kurasoin B (1), isolated in 1996 by Uchida et al, selectively inhibits Farnesyltransferase (FTase), an enzyme responsible for activating human RAS proteins (ref. 1). When RAS proteins are mutated and then activated, they contribute 20 to 30 percent of all human tumors, including those of the pancreas, colon, small intestine, lung, prostate, liver, skin, and thyroid, as well as multiple myeloma and a number of leukemias (ref. 2). Kurasoin B, therefore, has great potential as a cancer drug lead.
Phase-Transfer Catalyzed Asymmetric Synthesis Of S-Naproxen, M. A. Binkley, Michael A. Christiansen, K. H. Harper, M. B. Andrus
Phase-Transfer Catalyzed Asymmetric Synthesis Of S-Naproxen, M. A. Binkley, Michael A. Christiansen, K. H. Harper, M. B. Andrus
Chemistry and Biochemistry Faculty Presentations
This presentation explores a modified approach to Kurasoin B.